{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:44Z","timestamp":1788026324415,"version":"build-2784847793"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with moderate-to-severe atopic dermatitis (AD) require long-term management. Understanding the long-term safety of new treatments is a top priority for patients and healthcare professionals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety of tralokinumab in adults and adolescents with moderate-to-severe AD by conducting an integrated safety analysis of seven placebo-controlled trials and the ongoing, open-label extension study ECZTEND (NCT03587805).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An initial 16-week placebo-controlled (PBO-CTRL) safety set and an all-tralokinumab (ALL-TRALO) safety set combining the placebo-controlled trials and ECZTEND (data cutoff 30 April 2022) were analysed. All treatment-emergent adverse events were recorded. Adverse events of special interest (AESIs) were predefined. Safety areas of clinical interest for advanced systemic AD treatments were captured retrospectively. Proportions of patients with events and incidence rates (IRs) per 100 patient-years of exposure (PYE) were calculated. PYE was defined as the time until the first event or exposure end, whichever came first, and incidence was defined as the first event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Safety results were similar between the PBO-CTRL safety set and ALL-TRALO safety set. In the latter, 2693 patients received tralokinumab for up to 238.5 weeks (approximately 4.5\u2005years, PYE = 5320.2). Most adverse events (AEs) were nonserious, mild or moderate in severity, and occurred with similar frequencies between tralokinumab and placebo in the PBO-CTRL safety set. The most common AEs that occurred at higher rates for tralokinumab vs. placebo were nasopharyngitis [IR ratio (IRR) comparing tralokinumab vs. placebo 1.26], conjunctivitis (IRR 3.11) and injection site reaction (IRR 19.57). Dermatitis atopic and asthma occurred at lower rates with tralokinumab vs. placebo (IRR 0.51 and IRR 0.57, respectively). AESI eye disorders occurred at higher rates with tralokinumab vs. placebo (IRR 2.43) and 98% were mild to moderate. AESIs that were less frequent with tralokinumab vs. placebo included skin infections requiring systemic treatment (IRR 0.43) and eczema herpeticum (IRR 0.32). Rates of AEs of clinical interest (related to other approved systemic AD treatments) were low and similar between treatment groups. IRs of AEs did not increase with longer exposure in the ALL-TRALO safety set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term use of tralokinumab in adults and adolescents with moderate-to-severe AD was well-tolerated and consistent with the initial placebo-controlled treatment period, with no new safety signals identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf309","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:46:38Z","timestamp":1756295198000},"page":"225-235","source":"Crossref","is-referenced-by-count":9,"title":["Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5\u2005years: an integrated analysis of eight clinical trials"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"first","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-2164","authenticated-orcid":false,"given":"Richard G","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Clinical Dermatology and Cutaneous Science, Dalhousie University , Halifax, NS ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-6338","authenticated-orcid":false,"given":"Juan Francisco","family":"Silvestre Salvador","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario Dr Balmis , ISABIAL, Alicante ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4212","authenticated-orcid":false,"given":"Delphine","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Lille, INFINITE (Institute for Translational Research) U1286 Inserm, University of Lille , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Skin Pathology Laboratory, Humanitas Research Hospital IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5539","authenticated-orcid":false,"given":"Andrew E","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 Hospitals , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy \u00a0S","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[{"name":"Kyoto Prefectural University of Medicine Graduate School of Medical Science ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Augsburg , Augsburg ,","place":["Germany"]},{"name":"Department of Dermatology and Allergy, Ludwig-Maximilian University , Munich ,","place":["Germany"]},{"name":"Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust , Manchester ,","place":["UK"]},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, LLC , Annapolis, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-1761","authenticated-orcid":false,"given":"Christian","family":"Bjerreg\u00e5rd \u00d8land","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7185-7472","authenticated-orcid":false,"given":"Ann-Marie","family":"Tindberg","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-1397","authenticated-orcid":false,"given":"Le","family":"Gjerum","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric \u00a0L","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health and Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2026012706481325200_ljaf309-B1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"Stander","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012706481325200_ljaf309-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/bjd\/ljae138","article-title":"Blockade of IL-13 signalling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis","volume":"191","author":"Sander","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B3","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"key":"2026012706481325200_ljaf309-B4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026012706481325200_ljaf309-B5","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012706481325200_ljaf309-B8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-023-00817-0","article-title":"Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0\/1","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026012706481325200_ljaf309-B9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026012706481325200_ljaf309-B11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B13","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.70165","article-title":"Efficacy of up to 4\u2005years of tralokinumab in adults with moderate-to-severe atopic dermatitis","author":"Gooderham","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012706481325200_ljaf309-B14","doi-asserted-by":"crossref","first-page":"2345739","DOI":"10.1080\/09546634.2024.2345739","article-title":"Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment","volume":"35","author":"Feldman","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026012706481325200_ljaf309-B15","doi-asserted-by":"crossref","first-page":"2308682","DOI":"10.1080\/09546634.2024.2308682","article-title":"Patients\u2019 preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most","volume":"35","author":"Schaarschmidt","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026012706481325200_ljaf309-B16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"2026012706481325200_ljaf309-B17","doi-asserted-by":"crossref","first-page":"ii48","DOI":"10.1093\/bjd\/ljad498.050","article-title":"551 - Continuous tralokinumab treatment over 4\u2005years in adults with moderate-to-severe atopic dermatitis provides long-term disease control","volume":"190","author":"Blauvelt","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","article-title":"Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"85","author":"Merola","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B19","author":"LEO Pharma"},{"key":"2026012706481325200_ljaf309-B20","author":"US Food and Drug Administration"},{"key":"2026012706481325200_ljaf309-B21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/pst.1880","article-title":"Covariate adjustment and estimation of mean response in randomised trials","volume":"17","author":"Bartlett","year":"2018","journal-title":"Pharm Stat"},{"key":"2026012706481325200_ljaf309-B22","first-page":"1","article-title":"Various versatile variances: an object-oriented implementation of clustered covariances in R","volume":"95","author":"Zeileis","year":"2020","journal-title":"J \u00a0Stat Softw"},{"key":"2026012706481325200_ljaf309-B23","volume-title":"Adtralza\u00ae (tralokinumab): EPAR \u2013 Product Information (EMA Summary of Product Characteristics)","year":"2023"},{"key":"2026012706481325200_ljaf309-B24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.762","article-title":"43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate to severe atopic dermatitis: an interim analysis of ECZTEND","volume":"89","author":"Simpson","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026012706481325200_ljaf309-B28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Thaci","year":"2019","journal-title":"J Dermatol Sci"},{"key":"2026012706481325200_ljaf309-B29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026012706481325200_ljaf309-B30","article-title":"52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials","volume":"91","author":"Stein Gold","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B31","volume-title":"Dupixent\u00ae (dupilumab): EPAR \u2013 Product Information (EMA Summary of Product Characteristics)","year":"2024"},{"key":"2026012706481325200_ljaf309-B32","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin Immunol"},{"key":"2026012706481325200_ljaf309-B33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026012706481325200_ljaf309-B34","doi-asserted-by":"crossref","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6\u2005years and up to 3.9\u2005years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatol Treat"},{"key":"2026012706481325200_ljaf309-B35","first-page":"172","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"JACI"},{"key":"2026012706481325200_ljaf309-B36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe\u00a0atopic dermatitis: data from more than 5200 patient-years with\u00a0up to 4\u2005years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026012706481325200_ljaf309-B37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5114\/ada.2023.135764","article-title":"Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis","volume":"41","author":"Manzar","year":"2024","journal-title":"Postepy Dermatol Alergol"},{"key":"2026012706481325200_ljaf309-B38","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","article-title":"Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial","volume":"88","author":"Beck","year":"2023","journal-title":"J \u00a0Am Acad Dermatol"},{"key":"2026012706481325200_ljaf309-B39","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2\u2005years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"2026012706481325200_ljaf309-B40","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3390\/microorganisms9071487","article-title":"Changes in skin and nasal microbiome and staphylococcal species following treatment of atopic dermatitis with dupilumab","volume":"9","author":"Olesen","year":"2021","journal-title":"Microorganisms"},{"key":"2026012706481325200_ljaf309-B41","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jaip.2023.04.052","article-title":"Phenotypic and endotypic determinants of atopic dermatitis severity from the Atopic Dermatitis Research Network (ADRN) registry","volume":"11","author":"Simpson","year":"2023","journal-title":"J \u00a0Allergy Clin Immunol Pract"},{"key":"2026012706481325200_ljaf309-B42","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","article-title":"Association between atopic eczema and cancer in England and Denmark","volume":"156","author":"Mansfield","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf309\/64161144\/ljaf309.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf309\/64161144\/ljaf309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf309\/64161144\/ljaf309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:48:23Z","timestamp":1769514503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/2\/225\/8243959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf309","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,8,29]]}}}